{"id":9232,"date":"2025-11-22T13:35:15","date_gmt":"2025-11-22T10:35:15","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9232"},"modified":"2025-11-22T13:35:15","modified_gmt":"2025-11-22T10:35:15","slug":"jordan-cardiac-society-jcs-taskforce-congress-october-2025-supraventricular-tachycardia-svt-management-protocols","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/jordan-cardiac-society-jcs-taskforce-congress-october-2025-supraventricular-tachycardia-svt-management-protocols\/","title":{"rendered":"Jordan Cardiac Society (JCS) Taskforce Congress, October 2025 Supraventricular Tachycardia (SVT) Management Protocols"},"content":{"rendered":"

Jordan Cardiac Society (JCS) Taskforce Congress, October 2025<\/span><\/p>\n

Supraventricular Tachycardia (SVT)<\/span> Management Protocols<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Source: JCS Task Force 2025\u2013 EP Session, Dr. Munir <\/span>Zaqqa<\/span> (Interventional EP Cardiologist)<\/span><\/p>\n

Basil Abu El Haija, MD and Munir <\/span>Zaqqa<\/span>,<\/span> MD<\/span><\/p>\n

Keynotes:<\/span><\/p>\n

1. Definition<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>SVT = abnormal heart rhythm > 100 bpm.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Originates from the His bundle or above (atrial or AV nodal tissue).<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2. Clinical Presentation<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Main symptom: palpitations.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Other possible symptoms: dyspnea, fatigue, light-headedness, chest discomfort, syncope, or may be asymptomatic.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

3. Initial Assessment Algorithm<\/span><\/p>\n

\u200b<\/span>1.<\/span>\u200b<\/span>Assess patient \u2192 Check vital signs and hemodynamic stability.<\/span><\/p>\n

\u200b<\/span>2.<\/span>\u200b<\/span>Obtain ECG to confirm tachycardia type.<\/span><\/p>\n

\u200b<\/span>3.<\/span>\u200b<\/span>If sinus rhythm: search for underlying cause (anxiety, volume depletion, PE, etc.).<\/span><\/p>\n

\u200b<\/span>4.<\/span>\u200b<\/span>If SVT: determine if patient is stable.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

4. Unstable Patient<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Immediate cardioversion (50\u2013200 J synchronized).<\/span><\/p>\n

\u00a0<\/span><\/p>\n

5. Stable Patient \u2013 Stepwise Treatment<\/span><\/p>\n

\u200b<\/span>1.<\/span>\u200b<\/span>Assess mechanism on ECG:<\/span><\/p>\n

A regular narrow-complex tachycardia usually indicates a reentry mechanism, while an irregular pattern suggests atrial fibrillation or other non-reentrant causes (e.g., AF, MAT).<\/span><\/p>\n

\u200b<\/span>2.<\/span>\u200b<\/span>Regular SVT (reentry type):<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Perform Valsalva maneuver (first step).<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>If not converted \u2192 Adenosine 6\u201318 mg rapid IV bolus with escalation.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>If still not converted \u2192 AV-nodal blocking agents (beta-blocker or non-DHP CCB).<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>If ineffective \u2192 Antiarrhythmic agents (flecainide, propafenone, amiodarone) \u2014 avoid contraindications.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Cardioversion if pharmacologic treatment fails.<\/span><\/p>\n

\u200b<\/span>3.<\/span>\u200b<\/span>Irregular tachycardia: manage according to specific protocol (e.g., AF or MAT).<\/span><\/p>\n

\u00a0<\/span><\/p>\n

6. Long-Term Management<\/span><\/p>\n

\u00a0<\/span><\/p>\n

a. Patient Education<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Avoid caffeine, alcohol, and stress triggers.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Regular follow-ups for symptom control and drug side effects.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Monitor heart rhythm and adherence to therapy.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Watch for recurrence or complications.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

b. <\/span>Electrophysiologic Study & Ablation<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Recommended to avoid long-term medications and prevent recurrent hospitalizations.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Curative success rates > 95 % for AVNRT\/AVRT with low risk of complications.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

c. <\/span>Pharmacologic Therapy<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>\u03b2-blockers (metoprolol 25\u2013100 mg daily; bisoprolol 2.5\u201310 mg daily).<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Calcium-channel blockers (diltiazem 120\u2013360 mg; verapamil 120\u2013240 mg).<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Antiarrhythmics (flecainide, propafenone, amiodarone) \u2014 reserve for refractory cases under specialist supervision.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

7. Key Take-Home Messages<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Follow a structured algorithm for SVT recognition and management.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Early ECG confirmation and stability assessment are crucial.<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Adenosine remains the first-line acute drug for regular narrow complex tachycardia<\/span> that can act as a cure and\/or as a diagnostic tool. Record Rhythm strips and ECG while giving adenosine is crucial to diagnosis<\/span><\/p>\n

\u200b<\/span>\u2022<\/span>\u200b<\/span>Catheter ablation is the definitive therapy for SVT.<\/span><\/p>\n

\u2022 <\/span>\u00a0 \u00a0 \u00a0 Pharmacologic therapy can be given as a bridge to catheter ablation or if patient \u00a0 \u00a0is a high risk or prefers medications over invasive therapy<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

Jordan Cardiac Society (JCS) Taskforce Congress, October 2025 Supraventricular Tachycardia (SVT) Management Protocols \u00a0 Source: JCS Task Force 2025\u2013 EP Session, Dr. Munir Zaqqa (Interventional EP Cardiologist) Basil Abu El Haija, MD and Munir Zaqqa, MD Keynotes: 1. Definition \u200b\u2022\u200bSVT = abnormal heart rhythm > 100 bpm. \u200b\u2022\u200bOriginates from the His bundle or above (atrial […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9232","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9232"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9232\/revisions"}],"predecessor-version":[{"id":9233,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9232\/revisions\/9233"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}